219,488 Shares in Fulcrum Therapeutics, Inc. $FULC Bought by Braidwell LP

Braidwell LP acquired a new stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 219,488 shares of the company’s stock, valued at approximately $2,019,000. Braidwell LP owned approximately 0.41% of Fulcrum Therapeutics at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Strs Ohio raised its stake in shares of Fulcrum Therapeutics by 3.7% in the 3rd quarter. Strs Ohio now owns 77,900 shares of the company’s stock valued at $717,000 after purchasing an additional 2,800 shares during the period. Farther Finance Advisors LLC boosted its position in shares of Fulcrum Therapeutics by 108.3% during the third quarter. Farther Finance Advisors LLC now owns 7,112 shares of the company’s stock worth $65,000 after buying an additional 3,697 shares during the period. Squarepoint Ops LLC boosted its position in shares of Fulcrum Therapeutics by 30.4% during the third quarter. Squarepoint Ops LLC now owns 17,826 shares of the company’s stock worth $164,000 after buying an additional 4,151 shares during the period. Russell Investments Group Ltd. grew its holdings in shares of Fulcrum Therapeutics by 47.5% during the third quarter. Russell Investments Group Ltd. now owns 13,731 shares of the company’s stock worth $126,000 after buying an additional 4,423 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in shares of Fulcrum Therapeutics by 137.9% during the third quarter. BNP Paribas Financial Markets now owns 14,274 shares of the company’s stock worth $131,000 after buying an additional 8,275 shares in the last quarter. 89.83% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Fulcrum Therapeutics news, Director Robert J. Gould sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $11.87, for a total transaction of $178,050.00. Following the transaction, the director owned 469,864 shares of the company’s stock, valued at $5,577,285.68. The trade was a 3.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 7.00% of the stock is currently owned by company insiders.

Fulcrum Therapeutics Trading Up 0.3%

Shares of FULC opened at $7.65 on Friday. The company’s fifty day simple moving average is $9.83 and its 200 day simple moving average is $9.60. Fulcrum Therapeutics, Inc. has a 1-year low of $2.32 and a 1-year high of $15.74. The company has a market cap of $509.49 million, a price-to-earnings ratio of -6.48 and a beta of 3.23.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its quarterly earnings data on Tuesday, February 24th. The company reported ($0.31) EPS for the quarter, meeting analysts’ consensus estimates of ($0.31). As a group, research analysts forecast that Fulcrum Therapeutics, Inc. will post -0.16 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. The Goldman Sachs Group restated a “positive” rating on shares of Fulcrum Therapeutics in a research note on Monday, December 8th. Royal Bank Of Canada lifted their price objective on shares of Fulcrum Therapeutics from $7.00 to $10.00 and gave the company a “sector perform” rating in a report on Monday, December 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Thursday, January 22nd. Leerink Partners reiterated an “outperform” rating on shares of Fulcrum Therapeutics in a research note on Tuesday, February 24th. Finally, Stifel Nicolaus set a $25.00 price target on shares of Fulcrum Therapeutics in a research report on Monday, December 8th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Fulcrum Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.00.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.